PRAX (Praxis Precision Medicines) OCF Margin %: 0.00% (As of Mar. 2026)


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $312.78
GF Value $30.36
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Praxis Precision Medicines OCF Margin %?

Praxis Precision Medicines PRAX +1.24% 38 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates PRAX with a GF Score™ of 38/100 and a GF Value™ of $30.36 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Praxis Precision Medicines ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Praxis Precision Medicines's Cash Flow from Operations for the three months ended in Mar. 2026 was $-86.15 Mil. Praxis Precision Medicines's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Praxis Precision Medicines's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Praxis Precision Medicines's current OCF Yield % is -3.24%.

The historical rank and industry rank for Praxis Precision Medicines's OCF Margin % or its related term are showing as below:


During the past 8 years, the highest OCF Margin % of Praxis Precision Medicines was -1540.48%. The lowest was -4541.72%. And the median was -3041.10%.

PRAX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Praxis Precision Medicines OCF Margin % Related Terms

Praxis Precision Medicines OCF Margin % Historical Data

* Premium members only.

The historical data trend for Praxis Precision Medicines's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Praxis Precision Medicines OCF Margin % Chart

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 -4,541.72 -1,540.48 0.00

Praxis Precision Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Praxis Precision Medicines OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Praxis Precision Medicines's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-249.068/0
= %

Praxis Precision Medicines's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-86.152/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Praxis Precision Medicines (PRAX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Praxis Precision Medicines and its competitors. According to the industry distribution chart, Praxis Precision Medicines ranks #999999 out of 960 companies in the Biotechnology industry.
Is Praxis Precision Medicines' OCF Margin % too high?
Praxis Precision Medicines' current OCF Margin % is 0.00%. Based on the distribution chart, Praxis Precision Medicines ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Praxis Precision Medicines has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Praxis Precision Medicines' OCF Margin % compare to KRYS and CYTK?
According to the Biotechnology industry distribution chart, Praxis Precision Medicines ranks #999999 out of 960 companies for OCF Margin %. This places Praxis Precision Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Praxis Precision Medicines and its competitors. Praxis Precision Medicines's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Praxis Precision Medicines stock overvalued right now?
Based on GuruFocus' analysis, Praxis Precision Medicines (PRAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $30.36, compared to a current price of $312.78 — trading 930.2% above its estimated fair value. The current OCF Margin % is 0.00%. Praxis Precision Medicines' overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Praxis Precision Medicines (PRAX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $312.78 is trading 930.2% above its estimated GF Value™ of $30.36. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • OCF Margin %: 0.00%
  • GF Value™: $30.36 vs. price of $312.78 (930.2% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$312.78
Price
$30.36
GF Value